Please assess the completion status of the following clinical trial:

Trial Title: Biomarkers In Hidradenitis Suppurativa Participants Receiving Brodalumab

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed Diagnosis of Hidradenitis Suppurativa by the PI~* Age 18 or older~* Moderate to Severe Hidradenitis Suppurativa as determined by the PI~Exclusion Criteria:~* Inflammatory Bowel Disease~* HIV Positive~* Active Hepatitis B or C Infection~* Pregnant or Breastfeeding~* no concurrent use of any systemic antibiotics/retinoids/imunosuppressants (require washout period of \>5 half lives)~* Any medical, psychological or social condition that, in the opinion of the investigator, would jeopardize the health or well being go the participant during any study procedures or the integrity of the data~* High Suicide Risk as determined by the Columbia Suicide Severity Rating Scale~* History of Keloid Scarring

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Brodalumab 210mg subcutaneously every 2 weeks for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).